Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Public ClinicalTrials.gov record NCT01065935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Study identification
- NCT ID
- NCT01065935
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Interventions
- ALN-RSV01 Drug
- Normal Saline Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- Mar 31, 2012
- Completion
- Apr 30, 2012
- Last update posted
- Feb 4, 2018
2010 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | Phoenix | Arizona | 85013 | — |
| Clinical Site | Los Angeles | California | 90033 | — |
| Clinical Site | Denver | Colorado | 80202 | — |
| Clinical Site | Tampa | Florida | 33606 | — |
| Clinical Site | Atlanta | Georgia | 30322 | — |
| Clinical Site | Chicago | Illinois | 60153 | — |
| Clinical Site | Chicago | Illinois | 60637 | — |
| Clinical Site | Boston | Massachusetts | 02114 | — |
| Clinical Site | Boston | Massachusetts | 02115 | — |
| Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Clinical Site | St Louis | Missouri | 63110 | — |
| Clinical Site | New York | New York | 10032 | — |
| Clinical Site | Cleveland | Ohio | 44195 | — |
| Clinical Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Site | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Site | Nashville | Tennessee | 37232 | — |
| Clinical Site | Dallas | Texas | 75390 | — |
| Clinical Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01065935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2018 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01065935 live on ClinicalTrials.gov.